[144] Neuronetics, Inc. SEC Filing
Neuronetics, Inc. (Form 144) filed a notice proposing the sale of 381,640 shares of Common stock through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 08/08/2025 and an aggregate market value of $1,419,700.80 against 66,124,820 shares outstanding. The shares to be sold were acquired from the issuer in a merger/acquisition on 12/10/2024.
The filing shows the purchase was paid in cash on 12/10/2024, reports no securities sold in the past three months, and includes the required signer representation that the seller is not aware of undisclosed material adverse information about the issuer. The notice identifies the executing broker and the exchange but provides no further financial results or forward guidance.
Neuronetics, Inc. (Form 144) ha presentato un avviso proponendo la vendita di 381,640 azioni ordinarie tramite Morgan Stanley Smith Barney LLC sul NASDAQ, con data di vendita indicativa 08/08/2025 e un valore di mercato complessivo di circa $1,419,700.80 rispetto a 66,124,820 azioni in circolazione. Le azioni da vendere sono state acquisite dall'emittente in una fusione/acquisizione il 12/10/2024.
L'avviso riporta che l'acquisto 猫 stato pagato in contanti il 12/10/2024, dichiara nessuna vendita di titoli negli ultimi tre mesi e include la dichiarazione richiesta dal firmatario secondo cui il venditore non 猫 a conoscenza di informazioni sfavorevoli materiali non divulgate sull'emittente. L'avviso identifica il broker esecutore e la borsa, ma non fornisce ulteriori risultati finanziari n茅 indicazioni prospettiche.
Neuronetics, Inc. (Form 144) present贸 un aviso proponiendo la venta de 381,640 acciones ordinarias a trav茅s de Morgan Stanley Smith Barney LLC en el NASDAQ, con fecha aproximada de venta 08/08/2025 y un valor de mercado agregado de aproximadamente $1,419,700.80 frente a 66,124,820 acciones en circulaci贸n. Las acciones a vender se adquirieron del emisor en una 蹿耻蝉颈贸苍/补诲辩耻颈蝉颈肠颈贸苍 el 12/10/2024.
La presentaci贸n indica que la compra fue pagada en efectivo el 12/10/2024, declara ninguna venta de valores en los 煤ltimos tres meses e incluye la representaci贸n requerida del firmante de que el vendedor no tiene conocimiento de informaci贸n adversa material no divulgada sobre el emisor. El aviso identifica al corredor ejecutor y la bolsa, pero no ofrece m谩s resultados financieros ni orientaci贸n a futuro.
Neuronetics, Inc. (Form 144)電� Morgan Stanley Smith Barney LLC毳� 韱淀暣 NASDAQ鞐愳劀 381,640 氤错喌欤茧ゼ 毵り皝頃� 瓴冹潉 鞝滌晥頃橂姅 韱奠毳� 鞝滌稖頄堨溂氅�, 鞓堨爼 毵り皝鞚检潃 08/08/2025, 齑� 鞁滉皜齑濎暋鞚� 鞎� $1,419,700.80鞚搓碃 氚滍枆欤检嫕靾橂姅 66,124,820欤检瀰雼堧嫟. 毵る弰 雽�靸� 欤检嫕鞚� 12/10/2024鞐� 氚滍枆靷攵�韯� 顷╇硲/鞚胳垬毳� 韱淀暣 旆摑霅� 瓴冹瀰雼堧嫟.
靹滊鞐愲姅 頃措嫻 毵れ瀰鞚� 顺勱笀鞙茧 12/10/2024鞐� 歆�旮夒悩鞐堦碃, 瓿缄卑 3臧滌洈 霃欖晥 毵る弰頃� 歃濌秾鞚� 鞐嗢潓鞚� 氤搓碃頃橂┌, 毵る弰鞚胳澊 氚滍枆靷棎 雽�頃� 氙戈车臧� 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岇 氇豁暅雼る姅 靹滊獏鞚胳潣 歆勳垹鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟. 韱奠電� 鞁ろ枆 欷戧皽鞚戈臣 瓯半灅靻岆ゼ 氇呾嫓頃橃毵� 於旉皜鞝侅澑 鞛鞁れ爜鞚措倶 頄ロ泟 鞝勲鞚� 鞝滉车頃橃 鞎婌姷雼堧嫟.
Neuronetics, Inc. (Form 144) a d茅pos茅 un avis proposant la vente de 381,640 actions ordinaires par l'interm茅diaire de Morgan Stanley Smith Barney LLC sur le NASDAQ, avec une date de vente approximative le 08/08/2025 et une valeur marchande globale d'environ $1,419,700.80 sur 66,124,820 actions en circulation. Les actions 脿 vendre ont 茅t茅 acquises de l'茅metteur lors d'une fusion/acquisition le 12/10/2024.
Le d茅p么t indique que l'achat a 茅t茅 pay茅 en 别蝉辫猫肠别蝉 le 12/10/2024, d茅clare aucune cession de titres au cours des trois derniers mois et inclut la d茅claration requise du signataire selon laquelle le vendeur n'a pas connaissance d'informations d茅favorables mat茅rielles non divulgu茅es concernant l'茅metteur. L'avis identifie le courtier ex茅cutant et la bourse, mais ne fournit pas d'autres r茅sultats financiers ni d'orientations futures.
Neuronetics, Inc. (Form 144) reichte eine Mitteilung ein, in der der Verkauf von 381,640 Stammaktien 眉ber Morgan Stanley Smith Barney LLC an der NASDAQ vorgeschlagen wird, mit einem ungef盲hren Verkaufstermin 08/08/2025 und einem aggregierten Marktwert von rund $1,419,700.80 驳别驳别苍眉产别谤 66,124,820 ausstehenden Aktien. Die zu ver盲u脽ernden Aktien wurden im Rahmen einer 贵耻蝉颈辞苍/脺产别谤苍补丑尘别 am 12/10/2024 vom Emittenten erworben.
Die Einreichung weist aus, dass der Kauf am 12/10/2024 in Bargeld bezahlt wurde, meldet keine Verk盲ufe von Wertpapieren in den letzten drei Monaten und enth盲lt die erforderliche Erkl盲rung des Unterzeichners, dass der Verk盲ufer nicht 眉ber nicht offengelegte, wesentliche nachteilige Informationen 眉ber den Emittenten informiert sei. Die Mitteilung nennt den ausf眉hrenden Broker und die B枚rse, liefert jedoch keine weiteren finanziellen Ergebnisse oder zukunftsgerichteten Angaben.
- Execution through a registered broker (Morgan Stanley Smith Barney LLC) is disclosed, supporting an orderly market sale.
- Full cash payment for the acquired securities on 12/10/2024 is stated, clarifying consideration.
- No securities sold in the past three months is reported, limiting immediate concerns about recent insider sales.
- None.
Insights
TL;DR Routine Form 144 disclosing a modest proposed sale of 381,640 shares; limited immediate market impact given disclosure details.
The filing presents a straightforward proposed sale executed through a broker with a stated aggregate value of $1,419,700.80. The securities were acquired in a merger/acquisition on 12/10/2024 and paid in cash the same day, suggesting the position arose from corporate transaction activity rather than open-market accumulation. The filer reports no sales in the past three months, which reduces concerns about immediate prior dilution. Absent additional company financials or insider context, this notice is informational and does not itself change the company鈥檚 financial picture.
TL;DR Disclosure aligns with Rule 144 requirements; sale is broker-facilitated and tied to a recent merger/acquisition.
The form identifies the broker (Morgan Stanley Smith Barney LLC) and exchange (NASDAQ), and documents the acquisition source as the issuer via a merger on 12/10/2024. The filer affirms no undisclosed material adverse information and indicates no recent sales, meeting standard attestation language. This is a compliance-focused disclosure rather than a corporate governance event that alters board or management composition.
Neuronetics, Inc. (Form 144) ha presentato un avviso proponendo la vendita di 381,640 azioni ordinarie tramite Morgan Stanley Smith Barney LLC sul NASDAQ, con data di vendita indicativa 08/08/2025 e un valore di mercato complessivo di circa $1,419,700.80 rispetto a 66,124,820 azioni in circolazione. Le azioni da vendere sono state acquisite dall'emittente in una fusione/acquisizione il 12/10/2024.
L'avviso riporta che l'acquisto 猫 stato pagato in contanti il 12/10/2024, dichiara nessuna vendita di titoli negli ultimi tre mesi e include la dichiarazione richiesta dal firmatario secondo cui il venditore non 猫 a conoscenza di informazioni sfavorevoli materiali non divulgate sull'emittente. L'avviso identifica il broker esecutore e la borsa, ma non fornisce ulteriori risultati finanziari n茅 indicazioni prospettiche.
Neuronetics, Inc. (Form 144) present贸 un aviso proponiendo la venta de 381,640 acciones ordinarias a trav茅s de Morgan Stanley Smith Barney LLC en el NASDAQ, con fecha aproximada de venta 08/08/2025 y un valor de mercado agregado de aproximadamente $1,419,700.80 frente a 66,124,820 acciones en circulaci贸n. Las acciones a vender se adquirieron del emisor en una 蹿耻蝉颈贸苍/补诲辩耻颈蝉颈肠颈贸苍 el 12/10/2024.
La presentaci贸n indica que la compra fue pagada en efectivo el 12/10/2024, declara ninguna venta de valores en los 煤ltimos tres meses e incluye la representaci贸n requerida del firmante de que el vendedor no tiene conocimiento de informaci贸n adversa material no divulgada sobre el emisor. El aviso identifica al corredor ejecutor y la bolsa, pero no ofrece m谩s resultados financieros ni orientaci贸n a futuro.
Neuronetics, Inc. (Form 144)電� Morgan Stanley Smith Barney LLC毳� 韱淀暣 NASDAQ鞐愳劀 381,640 氤错喌欤茧ゼ 毵り皝頃� 瓴冹潉 鞝滌晥頃橂姅 韱奠毳� 鞝滌稖頄堨溂氅�, 鞓堨爼 毵り皝鞚检潃 08/08/2025, 齑� 鞁滉皜齑濎暋鞚� 鞎� $1,419,700.80鞚搓碃 氚滍枆欤检嫕靾橂姅 66,124,820欤检瀰雼堧嫟. 毵る弰 雽�靸� 欤检嫕鞚� 12/10/2024鞐� 氚滍枆靷攵�韯� 顷╇硲/鞚胳垬毳� 韱淀暣 旆摑霅� 瓴冹瀰雼堧嫟.
靹滊鞐愲姅 頃措嫻 毵れ瀰鞚� 顺勱笀鞙茧 12/10/2024鞐� 歆�旮夒悩鞐堦碃, 瓿缄卑 3臧滌洈 霃欖晥 毵る弰頃� 歃濌秾鞚� 鞐嗢潓鞚� 氤搓碃頃橂┌, 毵る弰鞚胳澊 氚滍枆靷棎 雽�頃� 氙戈车臧� 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岇 氇豁暅雼る姅 靹滊獏鞚胳潣 歆勳垹鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟. 韱奠電� 鞁ろ枆 欷戧皽鞚戈臣 瓯半灅靻岆ゼ 氇呾嫓頃橃毵� 於旉皜鞝侅澑 鞛鞁れ爜鞚措倶 頄ロ泟 鞝勲鞚� 鞝滉车頃橃 鞎婌姷雼堧嫟.
Neuronetics, Inc. (Form 144) a d茅pos茅 un avis proposant la vente de 381,640 actions ordinaires par l'interm茅diaire de Morgan Stanley Smith Barney LLC sur le NASDAQ, avec une date de vente approximative le 08/08/2025 et une valeur marchande globale d'environ $1,419,700.80 sur 66,124,820 actions en circulation. Les actions 脿 vendre ont 茅t茅 acquises de l'茅metteur lors d'une fusion/acquisition le 12/10/2024.
Le d茅p么t indique que l'achat a 茅t茅 pay茅 en 别蝉辫猫肠别蝉 le 12/10/2024, d茅clare aucune cession de titres au cours des trois derniers mois et inclut la d茅claration requise du signataire selon laquelle le vendeur n'a pas connaissance d'informations d茅favorables mat茅rielles non divulgu茅es concernant l'茅metteur. L'avis identifie le courtier ex茅cutant et la bourse, mais ne fournit pas d'autres r茅sultats financiers ni d'orientations futures.
Neuronetics, Inc. (Form 144) reichte eine Mitteilung ein, in der der Verkauf von 381,640 Stammaktien 眉ber Morgan Stanley Smith Barney LLC an der NASDAQ vorgeschlagen wird, mit einem ungef盲hren Verkaufstermin 08/08/2025 und einem aggregierten Marktwert von rund $1,419,700.80 驳别驳别苍眉产别谤 66,124,820 ausstehenden Aktien. Die zu ver盲u脽ernden Aktien wurden im Rahmen einer 贵耻蝉颈辞苍/脺产别谤苍补丑尘别 am 12/10/2024 vom Emittenten erworben.
Die Einreichung weist aus, dass der Kauf am 12/10/2024 in Bargeld bezahlt wurde, meldet keine Verk盲ufe von Wertpapieren in den letzten drei Monaten und enth盲lt die erforderliche Erkl盲rung des Unterzeichners, dass der Verk盲ufer nicht 眉ber nicht offengelegte, wesentliche nachteilige Informationen 眉ber den Emittenten informiert sei. Die Mitteilung nennt den ausf眉hrenden Broker und die B枚rse, liefert jedoch keine weiteren finanziellen Ergebnisse oder zukunftsgerichteten Angaben.
FAQ
What does the Neuronetics (STIM) Form 144 propose to sell?
When was the proposed sale for STIM scheduled to occur?
How and when were the securities being sold acquired?
Which broker and exchange are named in the Form 144 for STIM?
Has the filer sold any Neuronetics securities in the past three months?
